Business
Xeris Pharmaceuticals Signs Exclusive Agreement With Clinigen to Supply and Distribute Gvoke™ Outside the U.S on a Named Patient Basis
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced an exclusive agreement with Clinigen Group plc (AIM: CLIN, ‘Clinigen’) to manage the supply and distribution of Gvoke™ outside of the United States where Gvoke is not currently licensed.\n\n\n“In an effort to make ready-to-use Gvoke as accessible as possible to people with diabetes and in response to requests while our MAA is under review with the EMA, we have partnered with Clinigen, a distributor of unlicensed medicines. With Clinigen’s global infrastructure and expertise in the distribution of important unlicensed medicines, we can enable people with diabetes around the world to access Gvoke,” said Paul R. Edick, Chairman and CEO of Xeris. “It is especially important during this global health crisis that people with diabetes, who the CDC and others have identified as an at-risk population, have access to medicines like Gvoke, which can enable them to self-treat and avoid going to a busy hospital or medical center to receive care.”\n\n\nAll Gvoke product requests must be submitted by the treating physician on behalf of the patient. Healthcare professionals can obtain details about the Gvoke Managed Access Program by calling the Clinigen customer service team at +44 (0) 1283 494 340 or emailing [email protected]. Patients seeking medical information should contact their physician. Learn more at https://www.gvokeglucagon.com/hcp.\n\n\nAbout GVOKE™\n\n\nXeris received U.S. regulatory approval in 2019 for GVOKE™ (glucagon) injection, its ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above, and continues to evaluate additional applications to address needs in severe hypoglycemia and related conditions. Important Safety Information and a link to full prescribing information may be found at https://www.gvokeglucagon.com.\n\n\nAbout Xeris Pharmaceuticals, Inc.\n\n\nXeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day aro...